Drugs / Adderall
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04737512 | Feb 2021 → Oct 2024 | attention deficit-hyperactivity disorder | Yale University | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07664631 | Sep 2026 → Sep 2027 expected | post-traumatic stress disorder | University of Chicago | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03935646 | Feb 2020 → Jun 2025 | attention deficit-hyperactivity disorder, substance abuse | University of Wyoming | Unknown | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT04635826 | Jul 2025 → Jul 2029 | — | University of Alabama at Birmingham | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT04170738 | Nov 2019 → Aug 2023 | attention deficit-hyperactivity disorder, conduct disorder, substance abuse | Jeffrey Newcorn | Completed | No outcome recorded |
| Phase 4 | NCT03530631 | Nov → Dec 2018 | — | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT03420339 | Oct 2018 → Mar 2027 expected | attention deficit-hyperactivity disorder | Matthew J O'Brien, PhD, BCBA-D | Recruiting | No outcome recorded |
| Phase 4 | NCT02979327 | Jun 2018 → Jul 2021 | cardiovascular disorder | Mayo Clinic | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT01399827 Comparator | Feb 2012 → Nov 2017 | attention deficit-hyperactivity disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02204410 Background | Jul 2014 → May 2016 | attention deficit-hyperactivity disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01985581 Background | Oct 2013 → Mar 2015 | attention deficit-hyperactivity disorder | JPM van Stralen Medicine Professional | Completed | Met primary |
| — | NCT02142140 Comparator | Dec 2012 → Feb 2019 | attention deficit-hyperactivity disorder | McGill University Health Centre/Research Institute of the McGill University Health Centre | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adderall | “If Concerta +/- Ritalin is ineffective or not tolerated, participants will progress to Vyvanse; Adderall may be started if the effect of Vyvanse wears off mid-day;” NCT04737512 ↗12“patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)” NCT01985581 ↗ “Adderall” NCT04635826 ↗ “Adderall” NCT03420339 ↗ “Adderall” NCT02204410 ↗ “Adderall” NCT02142140 ↗ “Adderall” NCT01399827 ↗ |
| Known as | mixed amphetamine salts | “Adderall (generic: mixed amphetamine salts)” NCT07664631 ↗ |
| Route | Oral | “25 mg orally one time” NCT02979327 ↗ |